ClinicalTrials.Veeva

Menu

Study of EVP-6308 to Assess the Dose- and Concentration-dependent Displacement of [18F]MNI-659 by EVP-6308

F

FORUM Pharmaceuticals

Status and phase

Completed
Phase 1

Conditions

Healthy

Treatments

Drug: EVP-6308

Study type

Interventional

Funder types

Industry

Identifiers

NCT02001389
EVP-6308-002

Details and patient eligibility

About

This is an open-label, single-arm, multiple ascending dose Phase I study to assess the dose- and concentration-dependent displacement of [18F]MNI-659 [a PET tracer targeting phosphodiesterase 10 (PDE10)] by EVP-6308.

Enrollment

14 patients

Sex

All

Ages

18 to 50 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

• Healthy male or female volunteers, 18 to 50 years of age

Exclusion criteria

  • Clinically significant abnormalities on physical examination, medical history, ECG , vital signs, laboratory values, or unstable medical or psychiatric illness
  • Any disorder that may interfere with drug absorption.
  • Clinically significant allergy or sensitivity to medications Positive test for human immunodeficiency virus (HIV) antibodies, Hepatitis B surface antigen, or Hepatitis C antibody.
  • Pregnant or breast feeding.
  • History of exposure to any radiation >15 mSv/year (e.g., occupational or radiation therapy) over the past year.

Trial design

Primary purpose

Basic Science

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

14 participants in 4 patient groups

EVP-6308; Arm 1
Experimental group
Description:
low dose, Capsule, Twice Daily, Day 1 through Day 3
Treatment:
Drug: EVP-6308
EVP-6308; Arm 2
Experimental group
Description:
low intermediate dose, Capsule, Twice Daily, Day 1 through Day 3
Treatment:
Drug: EVP-6308
EVP-6308; Arm 3
Experimental group
Description:
high intermediate dose, Capsule, Once Daily, Day 1 through Day 3
Treatment:
Drug: EVP-6308
EVP-6308; Arm 4
Experimental group
Description:
high dose, Capsule, Once Daily, Day 1 through Day 3
Treatment:
Drug: EVP-6308

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems